Eli Lilly posts $15 bn quarterly revenue — obesity drugs outpace Novo Nordisk

Pharmaceutical giant Eli Lilly posted $15 billion in quarterly revenue, driven primarily by two obesity drugs. The results put Eli Lilly clearly ahead of rival Novo Nordisk in the race for the GLP-1 drug market. The obesity medication boom is becoming one of the biggest phenomena in the pharmaceutical industry in recent years.